CA19-9 elevation in ovarian mature cystic teratoma: Discrimination from ovarian cancer - CA19-9 level in teratoma

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 230-235

  Cho, Hye Yon ^a   Kim, Kidong ^b   Jeon, Yong Tark ^b   Kim, Yong Beom ^b   No, Jae Hong ^b  

^a Hallym University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

CA 125; CA 19 9; Mature cystic teratoma; Ovary cancer; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; FAT;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIFICATION; CANCER RISK; CHILD; CONFIDENCE INTERVAL; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVARIECTOMY; OVARY TERATOMA; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; TERATOMA;

EID: 84876886061     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883865     Document Type: Article

References (17)

1. Ayhan A, Bukulmez O, Genc C, Karamursel BS: Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol, 2000; 88: 153-57
2. Scharl A, Crombach G, Vierbuchen M et al: Antigen CA 19-9: presence in mucosa of nondiseased mullerian duct derivatives and marker for differentiation in their carcinomas. Obstet Gynecol, 1991; 77: 580-85
3. Rosen DG, Wang L, Atkinson JN et al: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005; 99: 267-77
4. Dede M, Gungor S, Yenen MC et al: CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer, 2006; 16: 189-93
5. Coskun A, Kiran G, Ozdemir O: CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol, 2008; 35: 137-39
6. Kyung MS, Choi JS, Hong SH, Kim HS: Elevated CA 19-9 levels in mature cystic teratoma of the ovary. Int J Biol Markers, 2009; 24: 52-56
7. Mais V, Guerriero S, Ajossa S et al: Transvaginal ultrasonography in the diagnosis of cystic teratoma. Obstet Gynecol, 1995; 85: 48-52
8. Quinn SF, Erickson S, Black WC: Cystic ovarian teratomas: the sonographic appearance of the dermoid plug. Radiology, 1985; 155: 477-78
9. Emin U, Tayfun G, Cantekin I et al: Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet, 2009; 279: 145-47
10. Kikkawa F, Nawa A, Tamakoshi K et al: Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer, 1998; 82: 2249-55
11. Ito K: CA19-9 in mature cystic teratoma. Tohoku J Exp Med, 1994; 172: 133-38
12. Saba L, Guerriero S, Sulcis R et al: Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol, 2009; 72: 454-63
13. Van Nagell JR Jr., Higgins RV, Donaldson ES et al: Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer, 1990; 65: 573-77
14. Jacobs I, Bast RC Jr.: The CA125 tumour-associated antigen: a review of the literature. Hum Reprod, 1989; 4: 1-12
15. Bischof P: What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol, 1993; 49: 93-98
16. Jacobs IJ, Skates S, Davies AP et al: Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ, 1996; 313: 1355-58
17. Jacobs IJ, Skates SJ, Macdonald N et al: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, 1999; 353: 1207-10